

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥(集團)股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

ANNOUNCEMENT ON THE APPROVAL FROM CSRC FOR THE PROPOSED NON-PUBLIC ISSUANCE

References are made to the announcements of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) dated 25 November 2020, 6 April 2021 and 12 July 2021, the overseas regulatory announcements of the Company dated 25 November 2020, 15 January 2021, 22 February 2021, 6 April 2021, 1 June 2021, 5 July 2021 and 12 July 2021, and the circular of the Company dated 8 December 2020 (the “**Circular**”), in relation to the Proposed Non-public Issuance. Unless otherwise specified, capitalised terms used in this announcement shall have the same meaning as defined in the Circular.

The Board is pleased to announce that the Company received the “Approval in relation to the Non-public Issuance of Shares by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.” (Zheng Jian Xu Ke [2021] No. 2501) issued by the CSRC on 30 July 2021. Details of the approval are as follows:

1. The Company is approved to undertake the non-public issuance of not more than 128,144,927 new Shares (A Shares), subject to adjustment in the event of change in the total share capital as a result of, among others, capital increase.
2. The issuance of shares shall be implemented strictly in accordance with the application documents submitted by the Company to the CSRC.
3. The CSRC approval shall be valid for a period of 12 months commencing from the date of the approval (27 July 2021).
4. The Company shall report, in a timely manner, to the CSRC in the event of occurrence of any material events during the period from the date of the approval for issuance and prior to the completion of the issuance of shares, and shall deal with such events in accordance with the relevant regulations.

The Board will deal with the matters pertaining the Proposed Non-public Issuance in accordance with the relevant requirements under the above approval from the CSRC and the relevant authorisation approved by the Shareholders at the general meeting of the Company, and will perform its information disclosure obligations in a timely manner.

Shareholders and potential investors shall exercise caution when dealing in the shares of the Company.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
Chairman

Shanghai, the PRC
2 August 2021

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* *for identification purposes only*